What is B. Riley’s Forecast for KYMR FY2025 Earnings?

Kymera Therapeutics, Inc. (NASDAQ:KYMR) – Analysts at B. Riley issued their FY2025 earnings estimates for shares of Kymera Therapeutics in a research report issued to clients and investors on Monday, March 3rd. B. Riley analyst K. Patel forecasts that the company will post earnings of ($3.95) per share for the year. The consensus estimate for Kymera Therapeutics’ current full-year earnings is ($2.79) per share. B. Riley also issued estimates for Kymera Therapeutics’ FY2026 earnings at ($4.46) EPS, FY2027 earnings at ($5.62) EPS and FY2028 earnings at ($5.82) EPS.

Kymera Therapeutics (NASDAQ:KYMR) last announced its quarterly earnings results on Thursday, February 27th. The company reported ($0.88) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.76) by ($0.12). The firm had revenue of $7.39 million for the quarter, compared to the consensus estimate of $14.81 million. Kymera Therapeutics had a negative net margin of 191.26% and a negative return on equity of 24.96%.

A number of other equities research analysts have also recently weighed in on the company. BTIG Research started coverage on Kymera Therapeutics in a report on Tuesday, December 10th. They set a “buy” rating and a $60.00 price target for the company. Leerink Partners restated an “outperform” rating and issued a $60.00 target price on shares of Kymera Therapeutics in a research note on Friday, December 27th. Stephens reaffirmed an “overweight” rating and issued a $60.00 price target on shares of Kymera Therapeutics in a report on Tuesday, January 21st. Morgan Stanley increased their price objective on shares of Kymera Therapeutics from $45.00 to $49.00 and gave the stock an “equal weight” rating in a report on Wednesday, November 6th. Finally, Wells Fargo & Company raised shares of Kymera Therapeutics from an “equal weight” rating to an “overweight” rating and boosted their target price for the stock from $38.00 to $57.00 in a research note on Monday, December 2nd. Three research analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $56.69.

Kymera Therapeutics Trading Up 1.7 %

NASDAQ:KYMR opened at $30.68 on Wednesday. The stock has a market capitalization of $1.99 billion, a P/E ratio of -13.11 and a beta of 2.18. Kymera Therapeutics has a 1 year low of $29.07 and a 1 year high of $53.27. The firm has a 50 day moving average of $38.60 and a 200-day moving average of $43.56.

Institutional Investors Weigh In On Kymera Therapeutics

A number of hedge funds have recently modified their holdings of the business. Blue Trust Inc. raised its holdings in shares of Kymera Therapeutics by 74.8% during the fourth quarter. Blue Trust Inc. now owns 631 shares of the company’s stock worth $25,000 after acquiring an additional 270 shares during the period. Summit Investment Advisors Inc. raised its stake in shares of Kymera Therapeutics by 9.0% in the 4th quarter. Summit Investment Advisors Inc. now owns 4,912 shares of the company’s stock valued at $198,000 after purchasing an additional 406 shares during the period. Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Kymera Therapeutics by 27.5% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,336 shares of the company’s stock valued at $114,000 after purchasing an additional 504 shares in the last quarter. Harbor Capital Advisors Inc. lifted its holdings in shares of Kymera Therapeutics by 1.7% in the fourth quarter. Harbor Capital Advisors Inc. now owns 40,987 shares of the company’s stock valued at $1,649,000 after purchasing an additional 684 shares in the last quarter. Finally, KBC Group NV boosted its position in shares of Kymera Therapeutics by 53.8% during the fourth quarter. KBC Group NV now owns 2,151 shares of the company’s stock worth $87,000 after buying an additional 752 shares during the period.

Insider Buying and Selling at Kymera Therapeutics

In related news, insider Ellen Chiniara sold 3,129 shares of Kymera Therapeutics stock in a transaction on Monday, January 6th. The stock was sold at an average price of $41.75, for a total transaction of $130,635.75. Following the completion of the sale, the insider now directly owns 54,826 shares of the company’s stock, valued at $2,288,985.50. The trade was a 5.40 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, COO Jeremy G. Chadwick sold 1,383 shares of the company’s stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $30.45, for a total value of $42,112.35. Following the completion of the sale, the chief operating officer now owns 67,800 shares of the company’s stock, valued at $2,064,510. This represents a 2.00 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 13,788 shares of company stock worth $455,202. Insiders own 15.82% of the company’s stock.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.